Drug Profile
MK 5475
Alternative Names: MK-5475Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Pulmonary arterial hypertension
- Phase II Pulmonary hypertension
Most Recent Events
- 25 Oct 2023 Merck initiates enrolment in a phase II trial for Pulmonary hypertension in Argentina, Australia, Colombia, Croatia, France, Germany, Isreal, Italy, Mexico, and the United Kingdom (NCT05612035)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Pulmonary-hypertension in Israel (Inhalation, Powder)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Pulmonary-hypertension in Moldova (Inhalation, Powder)